1 completed. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Completed 1 |
Follow Solid Tumor Malignancy: new trials by email Literature Review of Solid Tumor Malignancy trials Research Report on Solid Tumor Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy Messenger ribonucleic acid (mRNA)-1273 Vaccine, Messenger ribonucleic acid (mRNA)-1273 Vaccine Booster, ECG - Solid Tumor Malignancy, Hematologic Malignancy | Phase 2 | Completed | National Cancer Institute (NCI) | 19 | 2021-04-28 | 2024-08-27 |
Hematologic Neoplasms (1) · Leukemia (1) · Lymphoma (1) · Multiple Myeloma (1)
Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphatic Diseases (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Plasma Cell (1) · Paraproteinemias (1)
2019-nCoV Vaccine mRNA-1273 (1) · Anti-Bacterial Agents (1) · Antiemetics (1) · Antifungal Agents (1) · Electrocardiography (1) · RNA, Messenger (1)
National Cancer Institute (NCI) (1)
United States (1)